0151 GMT - Risks to Cochlear's earnings have increased since the April trading update that sparked a 41% one-day drop in the hearing-implant supplier's share price, Macquarie analysts warn. They point out that weaker U.S. consumer sentiment was a key factor in cochlear implant demand across the Australian company's 2026 fiscal year, which ended June 30. They observe that sentiment has further deteriorated since April's guidance cut, citing a recent escalation of U.S.-Iran tensions that generates further instability and potentially sticky consumer pessimism into fiscal 2027. Currency moves are also a significant headwind for revenues and gross margins, they add. Macquarie keeps a neutral rating on the stock and cuts its target price 3.4% to 115.00 Australian dollars. Shares are down 1.9% at A$119.85.